The reinstatement of coverage by Goldman Sachs with a Neutral rating and a specific price target provides investors with a professional analysis of Altimmune's stock value. While a Neutral rating does not suggest a strong buy or sell signal, the setting of a price target can serve as a benchmark for investors, potentially stabilizing the stock price around the target level if the market aligns with the analyst's view. However, the impact may be moderate as the rating is neutral, indicating that the analyst does not see significant upside or downside in the near term.